Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.
- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.
- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of...

Related Keywords

California ,United States ,Irvine ,China ,Tennessee ,Fosun Pharma ,Markj Foley ,Securities Exchange ,China National Medical Products Administration ,Viatris Inc ,Drug Administration ,Revance Therapeutics Inc ,Hint Inc ,Exchange Commission ,Linkedin ,Revance Therapeutics ,Athyrium Capital ,Note Purchase Agreement ,Second Tranche ,Third Tranche ,Chief Executive Officer ,Investor Day ,Quarter Highlights ,Relational Commerce ,National Medical Products Administration ,Hyaluronic Acid ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Consolidated Statements ,Months Ended June ,Revenue Breakdown ,Markets ,